Clinical Trails

Researchers have developed a new nanomaterial that destroys cancer cells by triggering a dual chemical attack inside tumors. The study, published in Advanced Functional Materials, improves chemodynamic therapy (CDT). Unlike traditional CDT agents that produce only one harmful molecule, this iron-based material generates both hydroxyl radicals and singlet oxygen. These highly reactive molecules damage DNA […]

Results from the phase 2 CYTOSHRINK trial show that adding Stereotactic Body Radiation Therapy (SBRT) to the immunotherapy combination of nivolumab and ipilimumab does not improve outcomes for patients with newly diagnosed advanced renal cell carcinoma (RCC). In fact, progression-free survival was shorter in the SBRT group (6.3 months) compared with immunotherapy alone (10.2 months).

Results from the LITESPARK-011 Phase 3 trial show that the combination of belzutifan (Welireg) and lenvatinib (Lenvima) is more effective than cabozantinib (Cabometyx) for patients with advanced clear cell renal cell carcinoma (ccRCC) previously treated with immunotherapy. The combination improved progression-free survival to 14.8 months compared with 10.7 months for cabozantinib, reducing the risk of disease progression or

Prostate cancer treatment has evolved from general hormone therapy to a personalized “ABCs + D” approach. While localized prostate cancer has a high 5-year survival rate, the focus is now on metastatic castration-resistant prostate cancer (mCRPC), which has historically had poor outcomes. Modern care emphasizes intensifying treatment earlier to achieve deeper responses. The “ABCs +

The Phase 3 SunRISE-2 study tested a new bladder drug-delivery system, Gem-iDRS, combined with the immunotherapy drug cetrelimab, in patients with muscle-invasive bladder cancer (MIBC) who did not undergo bladder removal. Gem-iDRS releases chemotherapy directly into the bladder over several weeks, while the control group received standard chemoradiotherapy (CRT), which combines radiation with systemic chemotherapy.

The RETAIN-1 and RETAIN-2 trials studied a new “risk-adapted” approach for treating muscle-invasive bladder cancer (MIBC). Instead of automatically removing the bladder with radical cystectomy, researchers wanted to find out which patients could safely keep their bladder through careful monitoring. In this approach, patients first received chemotherapy (MVAC) combined with immunotherapy (nivolumab) before surgery. Their

The Phase 3 KEYNOTE-B15/EV-304 trial compared a new treatment combination with standard cisplatin-based chemotherapy for patients with muscle-invasive bladder cancer (MIBC). For the first time in 25 years, a non-platinum regimen performed better than the usual cisplatin plus gemcitabine treatment. Patients received either enfortumab vedotin (EV) plus pembrolizumab before and after surgery, or cisplatin plus

The Phase 2 BRCAAway trial shows that combining abiraterone, prednisone, and olaparib is far more effective than using either drug alone for patients with metastatic castration-resistant prostate cancer who have BRCA1/2 or ATM mutations. Patients receiving the three-drug combination lived a median of 68 months—over five years—compared with 28 months for abiraterone alone and 37

Starton Therapeutics has treated the first patient in a Phase 2a study (NCT06087653) testing STAR-LLD, a new continuous under-the-skin (subcutaneous) form of lenalidomide, for people with relapsed or refractory multiple myeloma. Lenalidomide, sold as Revlimid, is commonly taken by mouth and is a standard treatment for multiple myeloma. However, when taken orally, the drug reaches

The phase 3 AEWS1031 study found that in patients with nonmetastatic Ewing sarcoma treated with interval-compressed chemotherapy, the choice of local treatment—surgery, radiation, or both—did not independently affect the risk of the cancer returning in the same area. The overall 5-year local recurrence rate was low at 6%, reflecting major improvements in modern, multi-modality care.